Form 8-K - Current report:
SEC Accession No. 0001558370-24-014148
Filing Date
2024-11-01
Accepted
2024-11-01 17:00:37
Documents
13
Period of Report
2024-11-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K adap-20241101x8k.htm   iXBRL 8-K 33715
  Complete submission text file 0001558370-24-014148.txt   154755

Data Files

Seq Description Document Type Size
2 EX-101.SCH adap-20241101.xsd EX-101.SCH 3505
3 EX-101.LAB adap-20241101_lab.xml EX-101.LAB 15973
4 EX-101.PRE adap-20241101_pre.xml EX-101.PRE 10792
15 EXTRACTED XBRL INSTANCE DOCUMENT adap-20241101x8k_htm.xml XML 4916
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 241419865
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)